Opinion|Videos|February 20, 2025
FLAURA and FLAURA2: Key Efficacy and Safety Data
Panelists discuss how osimertinib monotherapy demonstrated robust progression-free survival and overall survival benefits in FLAURA, while FLAURA2 showed that adding chemotherapy to osimertinib further improved progression-free survival (PFS) although overall survival (OS) data remains immature, leading to ongoing debate about the optimal first-line approach.
Advertisement
Video content above is prompted by the following:
- Please comment on the PFS and OS data for osimertinib monotherapy vs combination therapies in FLAURA and FLAURA2.
Advertisement
Related to this article
In TASKIN, the 12-month OS rate was 61.3% with vilamakitug vs 55.7% with placebo plus trifluridine/tipiracil.
The 510(k) clearance covers an MRI-derived AI risk score for stage I to IIIA disease; the high-risk category carried an HR of 2.81 for recurrence.
The FDA has approved dostarlimab for MSI-H or dMMR locally advanced rectal cancer.
The FDA accepted an NDA for UGN-103 for recurrent low-grade intermediate-risk NMIBC, with a target action date of June 14, 2027.
Ulrich Steidl, MD, PhD, has finalized his Montefiore Einstein Comprehensive Cancer Center senior leadership team.
The CirCLIQ Injector approval for subcutaneous isatuximab in multiple myeloma is the first anticancer treatment delivered via an on-body injector in Japan.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.
Moh’d Khushman, MD, discusses INCA33890’s mechanism of action, phase 1 safety and efficacy data, and the design of NEXERA-303 in MSS colorectal cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
2
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
3
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
4
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
5